Andrew Combs bought $69k of PRLD
Chief Chemistry Officer at Prelude Therapeutics Inc. 100,000 shares at an average of $0.69, traded Mar 25, 2025, filed Mar 27, 2025.
Score components
- +15RoleOfficer
- +8Trade size$69k at market
- +6Relative to holdingsHoldings up 26%
- 0Price contextNo price history yet
- 0ClusterNo other insider buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001562180-25-002779, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Mar 25, 2025 | POpen-market purchase Common Stock | +100,000 | $0.69 | $69k | 480,123 | Mar 27, 2025 |
Related signals
Other insiders at Prelude Therapeutics Inc and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 45Moderate | Prelude Therapeutics Inc | Andrew Combs Chief Chemistry Officer | $86k 63,075 shares | +20% | |
| 47Moderate | Prelude Therapeutics Inc | Bryant David Lim CLO, Interim CFO, Corp Sec. | $23k 25,000 shares | +1042% | |
| 53Moderate | Prelude Therapeutics Inc | Krishna Vaddi CEO | $99k 106,888 shares | +10% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.